v3.25.0.1
STOCK-BASED COMPENSATION (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Based Compensation Expense
(in thousands)202420232022
Cost of revenue$27,353 $28,994 $26,400 
Selling and marketing55,084 57,675 46,769 
Research and development29,838 31,039 29,266 
General and administrative30,443 25,644 19,775 
$142,718 $143,352 $122,210 
Income tax benefit$(1,799)$(2,187)$(1,881)
Schedule of Compensating Balances
(in thousands)202420232022
Compensation expense from 2006 ESPP$1,184 $1,367 $1,614 
Schedule of Weighted-Average Assumptions Used in Black-Scholes Option Valuation Model
The following table summarizes the Company’s fair value assumptions for stock options:
202420232022
Weighted-average grant-date fair value$25.82 $20.55 $17.49 
Assumptions used in the Black-Scholes option-pricing model:
Expected annual volatility (1)
49 %48 %42 %
Expected term in years (2)
3.93.53.9
Risk-free interest rate (3)
4.2 %4.2 %3.4 %
Expected annual dividend yield (4)
0.2 %0.1 %0.1 %
(1) The expected annual volatility for each grant is determined based on the average of historic daily price changes of the Company’s common stock over a period, which approximates the expected option term.
(2) The expected option term for each grant is determined based on the historical exercise behavior of employees and post-vesting employment termination behavior.
(3) The risk-free interest rate is based on the yield of U.S. Treasury securities with a commensurate maturity with the expected option term at the time of grant.
(4) The expected annual dividend yield is based on the weighted-average dividend yield assumptions used for options granted during the applicable period.
Schedule of Time-Based Vesting Stock Option Performance Stock Option Activity
The following table summarizes the time-based vesting stock option activity under the Company’s stock option plans for 2024:
Shares
(in thousands)		Weighted-average Exercise PriceWeighted-average Remaining Contractual Term (in years)
Aggregate Intrinsic Value
(in thousands) (1)
Options outstanding as of January 1, 202413,853 $59.32 
Granted1,857 62.90 
Exercised(1,937)43.94 
Forfeited(515)54.91 
Expired(284)90.16 
Options outstanding as of December 31, 202412,974 $61.63 
Vested and expected to vest as of December 31, 202411,477 $62.04 6.7$391,228 
Exercisable as of December 31, 20247,351 $65.37 5.8$232,270 
(1) The aggregate intrinsic value of stock options as of December 31, 2024 is based on the difference between the closing price of the Company’s stock of $93.20 and the exercise price of the applicable stock options.
The following table summarizes the Company’s performance stock option activity for 2024:
Shares
(in thousands)		Weighted-average Exercise PriceWeighted-average Remaining Contractual Term (in years)
Aggregate Intrinsic Value
(in thousands) (1)
Performance options outstanding as of January 1, 2024
886 $47.27 
Granted
566 62.10 
Exercised
(39)47.27 
Forfeited
(23)53.86 
Performance options outstanding as of December 31, 2024
1,390 $53.20 
Vested and expected to vest as of December 31, 20241,173 $53.12 8.6$47,001 
Exercisable as of December 31, 2024181 $47.27 8.2$8,304 
(1) The aggregate intrinsic value of stock options as of December 31, 2024 is based on the difference between the closing price of the Company’s stock of $93.20 and the exercise price of the applicable stock options.
Schedule of Combined Restricted Stock Units Activity
The following table summarizes the combined RSU activity for all grants, including the CICP, under the 2004 Plan for 2024:
Shares
(in thousands)		Weighted- Average Grant-Date
Fair Value		Aggregate Intrinsic Value
(in thousands)
Nonvested as of January 1, 20242,616 $64.85 
Granted1,366 62.57 
Vested(1,160)67.39 
Forfeited(209)63.78 
Nonvested as of December 31, 20242,613 $64.21 $243,516 
Expected to vest as of December 31, 20241,962 $63.39 $182,854